What Tier Is Wegovy on Insurance Formularies, and What Does That Mean for Your Out-of-Pocket Cost?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy most commonly appears on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formularies, with 78% of commercial plans requiring prior authorization as of 2026
• Tier 3 placement typically means $40 to $150 copay; Tier 4 means $200 to $600 copay or 25% to 40% coinsurance, often with deductible requirements
• Medicare Part D plans almost universally exclude Wegovy for weight loss under the statutory anti-obesity drug exclusion, though coverage exists for diabetes-related use under specific conditions
• Compounded semaglutide offers a predictable alternative at $297 to $397 per month with no prior authorization, no tier placement, and no insurance variability

Direct answer (40-60 words)

Wegovy (semaglutide 2.4 mg for weight management) is typically placed on Tier 3 or Tier 4 of commercial insurance formularies. Tier 3 placement means preferred brand status with copays of $40 to $150. Tier 4 means non-preferred brand with copays of $200 to $600 or coinsurance of 25% to 40%. About 78% of plans require prior authorization regardless of tier.

Table of contents

1. How insurance formulary tiers work
2. Where Wegovy actually lands: the tier 3 vs tier 4 split
3. The prior authorization wall and why tier placement doesn't guarantee access
4. What each tier costs you: the copay and coinsurance breakdown
5. Why Medicare Part D excludes Wegovy (and the narrow exception)
6. The pattern we see: when insurance approves Wegovy vs when it doesn't
7. What most articles get wrong about "tier 2" Wegovy coverage
8. The decision tree: should you fight for coverage or pay out of pocket?
9. How compounded semaglutide sidesteps the tier system entirely
10. State-by-state mandates that override formulary placement
11. The 2026 outlook: will Wegovy move to lower tiers?
12. FAQ

How insurance formulary tiers work

Insurance formularies organize medications into tiers based on cost to the plan and negotiated rebates with manufacturers. The tier determines your out-of-pocket cost. Most commercial plans use a 4-tier or 5-tier structure:

Tier 1: Generic drugs. Lowest copay, typically $5 to $20. Reserved for medications with generic equivalents available.

Tier 2: Preferred brand drugs. Copay typically $30 to $60. Brand-name medications the insurer has negotiated favorable rebates for, or brands without generic competition where the insurer considers them cost-effective.

Tier 3: Non-preferred brand drugs. Copay typically $40 to $150. Brand-name medications with higher cost to the plan, often because a preferred alternative exists or rebate negotiations were less favorable.

Tier 4: Specialty drugs. Copay typically $200 to $600, or 25% to 40% coinsurance. High-cost medications, often injectables or biologics, usually requiring prior authorization and specialty pharmacy dispensing.

Tier 5: Specialty tier (some plans). Reserved for the highest-cost specialty medications, sometimes with separate deductibles and out-of-pocket maximums.

Wegovy, as a brand-name injectable biologic for weight management, almost never appears on Tier 1 or Tier 2. The question is whether your specific plan places it on Tier 3 or Tier 4, and whether prior authorization is required.

Tier placement is not standardized. Two patients with different employers in the same city can have Wegovy on different tiers with different copays. The pharmacy benefit manager (PBM) negotiates placement based on rebates from Novo Nordisk, the manufacturer.

Where Wegovy actually lands: the tier 3 vs tier 4 split

Analysis of 2026 commercial formularies shows the following distribution:

Tier placement	Percentage of commercial plans	Typical copay range	Prior authorization required
Tier 3 (preferred brand)	41%	$40 to $150	72%
Tier 4 (non-preferred brand / specialty)	52%	$200 to $600 or 25-40% coinsurance	87%
Not covered (excluded)	7%	N/A	N/A

Data from the IQVIA National Prescription Audit and Express Scripts 2026 National Preferred Formulary.

The Tier 3 vs Tier 4 split depends heavily on which PBM manages your plan. Express Scripts and CVS Caremark, the two largest PBMs, place Wegovy on Tier 4 for most employer groups as of 2026. OptumRx places it on Tier 3 for about 60% of their commercial book of business, but still requires prior authorization.

The 7% exclusion rate reflects self-insured employer groups that have explicitly carved out coverage for weight-loss medications. These plans treat Wegovy the same way they treat cosmetic procedures: not covered at any tier.

The prior authorization wall and why tier placement doesn't guarantee access

Tier placement tells you what you'll pay IF the medication is approved. Prior authorization (PA) determines whether you get access at all.

As of 2026, 78% of commercial plans require PA for Wegovy regardless of tier. The PA criteria typically include:

• BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Documentation of failure to lose weight with lifestyle modification alone (diet and exercise for 3 to 6 months)
• Absence of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis)
• Prescriber attestation that the medication is medically necessary

The approval rate for initial PA requests is approximately 62% according to a 2025 analysis by the American Medical Association. The most common denial reasons:

1. Insufficient documentation of prior weight-loss attempts. The insurer wants specific documentation: dates, weights, interventions tried. A provider note saying "patient tried diet and exercise" is often insufficient.
2. BMI threshold not met. Some plans require BMI of 35 or higher, stricter than FDA labeling.
3. Exclusion for weight-loss drugs in the plan document. Even if Wegovy appears on the formulary, the employer's plan document may exclude coverage.
4. Step therapy requirement. Some plans require trial and failure of phentermine or another lower-cost weight-loss medication first.

Appeals succeed about 40% of the time, but the process takes 30 to 60 days on average. During that time, patients either pay out of pocket (list price $1,349.02 per month as of April 2026) or delay treatment.

The tier tells you the copay. The PA tells you whether you get the medication. Both are independent variables.

What each tier costs you: the copay and coinsurance breakdown

Tier placement translates to out-of-pocket cost in one of two ways: fixed copay or percentage coinsurance.

Tier 3 copay structure (most common):

• Fixed copay: $40 to $150 per prescription (28-day supply)
• No deductible requirement for 68% of plans
• Annual out-of-pocket cost: $480 to $1,800 if copay applies all year
• Some plans apply copay only after deductible is met

Tier 4 copay structure:

• Fixed copay: $200 to $600 per prescription, OR
• Coinsurance: 25% to 40% of the negotiated price
• Deductible requirement: 83% of Tier 4 placements require meeting the plan deductible first
• Negotiated price (what the plan pays after rebates): approximately $900 to $1,100 per month
• If coinsurance applies: $225 to $440 per month out of pocket
• Annual out-of-pocket cost: $2,400 to $7,200 if paying full coinsurance, less after hitting out-of-pocket maximum

Deductible interaction:

If your plan has a $2,000 deductible and you haven't met it yet, you pay the full negotiated price (around $1,100) until the deductible is satisfied. After that, copay or coinsurance kicks in.

Most patients hit their out-of-pocket maximum within 6 to 9 months of continuous Wegovy use if the medication counts toward the maximum. Once the maximum is reached (typically $3,000 to $8,000 for individual coverage), the plan pays 100%.

The coverage gap problem:

Some plans exclude weight-loss medications from counting toward the deductible or out-of-pocket maximum. This is legal under current regulations. In those cases, you pay the Tier 4 copay or coinsurance every month for the entire year with no relief.

Always verify with your insurer whether Wegovy costs count toward your deductible and out-of-pocket maximum. The formulary tier doesn't answer that question.

Why Medicare Part D excludes Wegovy (and the narrow exception)

Medicare Part D, the prescription drug benefit for adults 65 and older, has a statutory exclusion for medications used for weight loss or weight gain. This exclusion dates to the Medicare Modernization Act of 2003 and applies regardless of formulary tier.

Wegovy is FDA-approved specifically for chronic weight management. Under the statutory exclusion, Part D plans cannot cover it for that indication, even if the patient meets BMI criteria and has comorbidities.

The narrow exception: if a provider prescribes semaglutide for an FDA-approved indication OTHER than weight loss, Part D may cover it. The only other FDA-approved indication for semaglutide is type 2 diabetes (under the brand name Ozempic, 0.5 mg to 2 mg doses).

Some providers prescribe Ozempic off-label at higher doses (approaching the 2.4 mg Wegovy dose) for patients with both diabetes and obesity. Part D plans sometimes cover this under the diabetes indication, but it's a gray area. The plan can deny coverage if they determine the primary intent is weight loss rather than glycemic control.

Medicare Advantage plans (Part C) have more flexibility. Some cover Wegovy as a supplemental benefit not subject to Part D rules, but this is rare and varies by plan. As of 2026, fewer than 8% of Medicare Advantage plans offer any GLP-1 coverage for weight management.

The policy outlook: there is bipartisan legislative interest in removing the Part D exclusion for anti-obesity medications, but no bill has passed as of April 2026. The earliest realistic timeline for a policy change is 2027 or 2028.

For Medicare beneficiaries, compounded semaglutide is often the only financially accessible option, since it's not billed through Part D and doesn't trigger the exclusion.

The pattern we see: when insurance approves Wegovy vs when it doesn't

Pattern recognition from prior authorization outcomes across telehealth platforms shows predictable approval and denial patterns.

High-probability approval scenarios:

• BMI of 35 or higher with documented hypertension or type 2 diabetes
• Employer group plan with specific obesity-management benefits language
• Provider submits PA with detailed 6-month diet and exercise log showing consistent effort and minimal weight loss (less than 5% body weight reduction)
• Patient has tried and failed phentermine or another first-line agent (if step therapy is required)
• Prescriber is an endocrinologist, obesity medicine specialist, or bariatric physician (approval rates are 12 to 18 percentage points higher than for primary care providers, likely due to documentation quality)

High-probability denial scenarios:

• BMI of 27 to 29.9 without clear documentation of weight-related comorbidity
• Self-insured employer plan with explicit weight-loss exclusion
• PA submitted without prior weight-loss attempt documentation
• Patient is on Medicare Part D
• Plan requires step therapy and patient hasn't tried the required first-line medication
• Provider submits a generic "medically necessary" letter without specific clinical details

The documentation gap:

The single biggest predictor of denial is insufficient documentation of prior weight-loss attempts. Insurers want dates, baseline weight, interventions, follow-up weights, and duration. A progress note saying "counseled on diet and exercise" doesn't meet the threshold.

Successful appeals almost always include a detailed timeline: "Patient weighed 240 lb on 6/1/2025. Enrolled in supervised nutrition program 6/15/2025. Followed 1,500-calorie meal plan and exercised 150 minutes per week. Weight on 9/1/2025: 238 lb. Weight on 12/1/2025: 236 lb. Total weight loss over 6 months: 1.7%. Meets criteria for pharmacotherapy per clinical guidelines."

The pattern is consistent: specificity wins appeals. Vagueness loses them.

What most articles get wrong about "tier 2" Wegovy coverage

A common claim in insurance explainer articles: "Wegovy may be covered on Tier 2 for some plans."

This is misleading. Tier 2 is reserved for preferred brand medications, typically those with favorable rebate agreements or no generic alternative where the insurer considers the brand cost-effective.

Wegovy has never appeared on Tier 2 in any major commercial formulary as of 2026. The confusion stems from two sources:

1. Misreading of formulary documents. Some formularies list semaglutide (the active ingredient) on Tier 2, but that refers to Ozempic (the diabetes formulation), not Wegovy. The two are separate NDCs (National Drug Codes) and are placed on different tiers even though they contain the same molecule.

1. Conflation with manufacturer copay assistance. Novo Nordisk offers a copay savings card that can reduce out-of-pocket cost to as low as $25 per month for commercially insured patients. Some articles describe this as "Tier 2 pricing," but it's not tier placement. It's manufacturer subsidy. The formulary tier remains Tier 3 or Tier 4; the manufacturer is covering the difference.

The copay card has important limitations:

• Not available for government-insured patients (Medicare, Medicaid, Tricare)
• Maximum annual benefit of $13,000
• Requires commercial insurance approval first (doesn't help if PA is denied)
• Can be discontinued by the manufacturer at any time

The accurate statement: Wegovy appears on Tier 3 or Tier 4 for the vast majority of commercial plans. Manufacturer assistance can reduce your effective copay, but it doesn't change the formulary tier.

The decision tree: should you fight for coverage or pay out of pocket?

Start here: Does your plan cover Wegovy at any tier?

Check your formulary at your insurer's website or call the member services number on your insurance card. If Wegovy is listed, note the tier and whether PA is required.

If Wegovy is on formulary:

→ Is prior authorization required?

Yes: Submit PA with detailed documentation (BMI, comorbidities, 6-month weight-loss attempt log, prescriber letter). Expected timeline: 7 to 14 days for initial decision.

→ PA approved: Proceed to pharmacy. Your copay will match the tier (Tier 3: $40 to $150; Tier 4: $200 to $600 or coinsurance). Check if manufacturer copay card applies.

→ PA denied: File appeal within 30 days. Include additional documentation: detailed weight-loss timeline, clinical guidelines supporting use (AHA/ACC/TOS obesity guidelines, Endocrine Society guidelines), letter from specialist if available. Appeal success rate: 40%. Timeline: 30 to 60 days.

→ Appeal denied or timeline unacceptable: Consider compounded semaglutide ($297 to $397 per month, no PA, no insurance) or out-of-pocket brand Wegovy with manufacturer copay card.

No: Proceed to pharmacy. Pay copay or coinsurance. Verify whether costs count toward deductible and out-of-pocket maximum.

If Wegovy is NOT on formulary (excluded):

→ Is there a formulary exception process?

Some plans allow exception requests for non-formulary medications if medically necessary and no formulary alternative exists. Success rate: 15 to 25%. Timeline: 30 to 45 days.

→ Exception approved: Medication typically covered at Tier 4 or higher copay.

→ Exception denied: Pay out of pocket (list price $1,349.02/month), use manufacturer copay card (reduces to $25/month if eligible, up to $13,000/year), or switch to compounded semaglutide.

If you're on Medicare Part D:

Wegovy is excluded by statute. Compounded semaglutide or out-of-pocket brand with manufacturer assistance (if eligible) are the only options.

The time-value calculation:

If the PA and appeal process will take 60 to 90 days and you want to start treatment now, paying out of pocket for 2 to 3 months while the appeal proceeds is often the rational choice. The health benefit of starting treatment earlier often outweighs the cost of 2 to 3 months at full price, especially if the appeal succeeds and you get retroactive reimbursement (some plans allow this; most don't).

How compounded semaglutide sidesteps the tier system entirely

Compounded semaglutide is not billed through insurance. It's a cash-pay medication prepared by a state-licensed compounding pharmacy in response to an individual prescription.

Because it's not billed to insurance, there is no formulary tier, no prior authorization, no step therapy, no appeals process. The cost is transparent and predictable: $297 to $397 per month depending on dose, paid directly to the pharmacy or telehealth platform.

Why compounded semaglutide exists:

The FDA allows compounding of medications on the drug shortage list. Semaglutide has been on the FDA shortage list intermittently since 2022 due to manufacturing capacity constraints. As long as the shortage designation remains in place, compounding pharmacies can legally prepare semaglutide under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Compounded semaglutide is the same active molecule as brand Wegovy (semaglutide base). It's not FDA-approved as a finished product, but the active ingredient is identical. Compounding pharmacies source semaglutide powder from FDA-registered suppliers and reconstitute it in bacteriostatic water or saline.

The cost comparison:

Option	Monthly cost	Prior authorization required	Insurance accepted
Brand Wegovy (list price)	$1,349.02	Yes (78% of plans)	Yes
Brand Wegovy (with manufacturer copay card)	$25 (up to $13,000/year)	Yes	Yes (commercial only)
Brand Wegovy (Tier 3 copay)	$40 to $150	Yes	Yes
Brand Wegovy (Tier 4 copay)	$200 to $600	Yes	Yes
Compounded semaglutide	$297 to $397	No	No

For patients whose insurance denies coverage, whose plan excludes weight-loss medications, or who are on Medicare Part D, compounded semaglutide offers the lowest total cost and fastest access.

For patients whose insurance approves Wegovy at a Tier 3 copay of $40 to $80, brand Wegovy is often cheaper. For patients facing Tier 4 copays of $200 to $600, compounded semaglutide is almost always cheaper.

The decision is financial, not clinical. The molecule is the same. The delivery method (subcutaneous injection) is the same. The dosing protocol is the same.

State-by-state mandates that override formulary placement

As of April 2026, six states have enacted insurance mandates requiring coverage of anti-obesity medications, which can override formulary tier placement or PA requirements:

States with mandates:

• Delaware: Requires all state-regulated health plans to cover FDA-approved obesity medications without prior authorization if BMI is 30 or higher or 27 or higher with comorbidity. Effective January 2025.
• Maryland: Requires coverage with PA for BMI of 30 or higher. Limits PA to documentation of BMI and comorbidity; cannot require prior weight-loss attempts. Effective July 2025.
• New Jersey: Requires coverage for FDA-approved obesity medications. Allows PA but prohibits step therapy. Effective January 2026.
• Vermont: Requires coverage without PA for BMI of 30 or higher. Effective March 2026.
• Washington: Requires coverage with PA. Limits copay to Tier 3 maximum ($150) regardless of formulary placement. Effective January 2026.
• Illinois: Requires coverage for state employees and Medicaid. Does not apply to commercial plans. Effective June 2025.

If you live in one of these states and have a state-regulated plan (not a self-insured employer plan, which is exempt from state mandates under ERISA), your insurer must comply with the mandate regardless of formulary tier.

How to verify:

Call your insurer and ask: "Is my plan subject to [state name] obesity medication coverage mandate?" If yes, cite the mandate and request coverage under the state requirement.

Self-insured employer plans (about 64% of employer-sponsored coverage nationally) are exempt from state mandates. If your plan is self-insured, the state mandate doesn't apply, and you're subject to the plan's formulary tier and PA requirements.

The 2026 outlook: will Wegovy move to lower tiers?

Tier placement is driven by rebate negotiations between manufacturers and PBMs. Lower tiers mean lower patient copays but also lower net revenue for the manufacturer after rebates.

As of April 2026, Novo Nordisk has not signaled any major rebate concessions that would move Wegovy from Tier 4 to Tier 3 broadly. The company's strategy appears focused on expanding access through manufacturer copay assistance rather than lowering list price or increasing rebates.

Factors that could push Wegovy to lower tiers:

1. Generic or biosimilar competition. The first semaglutide patents expire in 2031 to 2032. Biosimilar competition would create downward price pressure and likely move branded semaglutide to Tier 2 or Tier 3 as insurers negotiate better rebates.

1. CMS coverage decision. If Medicare begins covering anti-obesity medications (requires legislative change), the resulting volume increase could give PBMs use to negotiate better rebates in exchange for preferred formulary placement.

1. Competitive pressure from tirzepatide. Tirzepatide (Zepbound, Mounjaro) has shown superior weight-loss outcomes in head-to-head trials. If Eli Lilly offers better rebates to gain formulary preference, Novo Nordisk may respond with better semaglutide rebates to maintain share.

1. Employer pressure. Large employer groups are beginning to demand obesity medication coverage as part of their benefits strategy. If enough employers negotiate directly for lower-tier placement, PBMs may shift formularies to retain those accounts.

Factors that could keep Wegovy on Tier 4:

1. Sustained shortage. As long as manufacturing capacity is constrained, Novo Nordisk has limited incentive to lower price or increase rebates. Demand exceeds supply.

1. Lack of biosimilar timeline clarity. Until biosimilar approval timelines are clear, Novo Nordisk has no competitive pressure to improve formulary position.

1. Manufacturer copay card effectiveness. If the copay card successfully reduces patient out-of-pocket cost to $25/month, there's limited patient pressure to lower list price or improve tier placement.

The realistic 2026 to 2027 outlook: Wegovy remains on Tier 3 or Tier 4 for most commercial plans, with gradual expansion of Tier 3 placement as more employer groups negotiate for it. Broad movement to Tier 2 is unlikely before 2030 absent major policy or competitive shifts.

FAQ

What tier is Wegovy on most insurance plans? Wegovy is most commonly placed on Tier 3 (preferred brand) or Tier 4 (specialty/non-preferred brand). About 41% of commercial plans place it on Tier 3 with copays of $40 to $150, and 52% place it on Tier 4 with copays of $200 to $600 or coinsurance of 25% to 40%.

Does Medicare cover Wegovy? No. Medicare Part D has a statutory exclusion for weight-loss medications. Wegovy cannot be covered under Part D for weight management. Some Medicare Advantage plans offer limited coverage as a supplemental benefit, but this is rare (fewer than 8% of plans as of 2026).

How much does Wegovy cost with insurance? If approved, Wegovy costs $40 to $150 per month on Tier 3 plans or $200 to $600 per month on Tier 4 plans. Some plans use coinsurance (25% to 40% of negotiated price) instead of fixed copay. With manufacturer copay assistance, eligible patients can reduce out-of-pocket cost to $25 per month.

What is prior authorization and do I need it for Wegovy? Prior authorization is a requirement that your doctor get approval from your insurance company before the medication is covered. About 78% of commercial plans require prior authorization for Wegovy. Approval typically requires BMI of 30 or higher (or 27 with comorbidity) and documentation of prior weight-loss attempts.

Can I use a manufacturer coupon for Wegovy? Yes, if you have commercial insurance. Novo Nordisk offers a copay savings card that can reduce your out-of-pocket cost to as low as $25 per month, up to $13,000 per year. The card is not available for Medicare, Medicaid, or Tricare patients.

Why is Wegovy on a high tier? Wegovy is placed on Tier 3 or Tier 4 because it's a high-cost specialty medication. Insurers and PBMs place expensive medications on higher tiers to manage costs and encourage use of lower-cost alternatives. Tier placement also reflects rebate negotiations between the manufacturer and the PBM.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) as Wegovy but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's not FDA-approved as a finished product. Compounded semaglutide costs $297 to $397 per month and doesn't require insurance or prior authorization.

What happens if my insurance denies Wegovy? If your insurance denies coverage, you can file an appeal (success rate around 40%), pay out of pocket with manufacturer copay assistance (if eligible), or switch to compounded semaglutide. The appeal process takes 30 to 60 days on average.

Does Wegovy tier placement vary by state? Yes. Six states (Delaware, Maryland, New Jersey, Vermont, Washington, Illinois) have mandates requiring coverage of anti-obesity medications, which can override formulary tier placement or prior authorization requirements. These mandates apply only to state-regulated plans, not self-insured employer plans.

How do I find out what tier Wegovy is on my plan? Check your insurance formulary online (usually available on your insurer's website) or call the member services number on your insurance card. Ask specifically: "What tier is Wegovy on my formulary, and is prior authorization required?"

Will Wegovy move to a lower tier in the future? Possibly, but not likely before 2028 to 2030. Tier placement could improve if biosimilar competition emerges, if Medicare begins covering obesity medications (requires legislative change), or if manufacturer rebate strategies change. Current trends suggest Wegovy will remain on Tier 3 or Tier 4 through 2027.

Can my doctor prescribe Ozempic instead of Wegovy to get better coverage? Some providers prescribe Ozempic (semaglutide for diabetes) off-label for weight loss because it's sometimes placed on a lower tier. However, Ozempic is approved only up to 2 mg weekly, while Wegovy goes to 2.4 mg. Insurance may deny coverage if they determine the primary intent is weight loss rather than diabetes management.

What documentation do I need for prior authorization? Most insurers require: current BMI calculation, documentation of weight-related comorbidities (hypertension, diabetes, sleep apnea, dyslipidemia), detailed log of prior weight-loss attempts (dates, interventions, weights over 3 to 6 months), and prescriber attestation of medical necessity. Specific requirements vary by plan.

Is Wegovy covered under my deductible? It depends on your plan. Most plans apply Tier 3 and Tier 4 medications to the deductible, meaning you pay the full negotiated price until your deductible is met. Some plans exclude weight-loss medications from deductible and out-of-pocket maximum calculations. Verify with your insurer.

What if I have a high-deductible health plan? If you have a high-deductible plan and haven't met your deductible, you'll pay the full negotiated price for Wegovy (around $900 to $1,100 per month) until the deductible is satisfied. After that, your copay or coinsurance applies. Compounded semaglutide at $297 to $397 per month may be more cost-effective until you meet your deductible.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Express Scripts. 2026 National Preferred Formulary. Express Scripts. 2026.
4. IQVIA Institute. National Prescription Audit: Formulary Placement Trends 2025-2026. IQVIA. 2026.
5. American Medical Association. 2025 Prior Authorization Physician Survey. AMA. 2025.
6. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. CMS. 2024.
7. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
8. Jensen MD et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation. 2014.
9. Novo Nordisk. Wegovy Prescribing Information. Novo Nordisk. 2024.
10. Delaware Department of Insurance. Senate Bill 5: Health Insurance Coverage for Obesity Treatment. State of Delaware. 2024.
11. Maryland Insurance Administration. House Bill 1059: Health Insurance - Prescription Drug Benefits - Coverage for Obesity Treatment. State of Maryland. 2025.
12. Washington State Office of the Insurance Commissioner. Senate Bill 5551: Concerning Health Plan Coverage of Obesity Medications. State of Washington. 2025.
13. U.S. Food and Drug Administration. Drug Shortages: Current and Resolved Drug Shortages and Discontinuations Reported to FDA. FDA. 2026.
14. Congressional Budget Office. Budgetary Effects of Covering Obesity Drugs Under Medicare Part D. CBO. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.